The combination of lily’s bimagrumab with vegovi helps to lose weight without muscle loss
A new study suggests that combination of Bimagrumab with vegovi causes significant fat loss without muscle loss. This success provides hope for the treatment of safe obesity but caution is taken on possible side effects.
In short
- Patients lost an average of 22.1% body weight in 48 weeks using both medicines.
- 92.8% weight loss was fat, to protect the muscles effectively
- Muscle loss is a common side effect in rapid weight loss treatment
A new study has found that two weight -weight drugs, including Elli Lily’s experimental drug Bimragrumab and Novo Nordisk’s vegovi, which contains semaglutide helps people to lose weight by retaining their muscles.
The findings presented at the American Diabetes Association Conference in Chicago showed that patients taking both drugs lost an average of 22.1% of their body weight in 48 weeks. According to Bloomberg report, 92.8% of that weight loss came from fat, not muscles.
Comparatively, people who only took Vagovi, with a loss of 15.7% of their weight, 71.8% of fat losses, indicate that more muscles were lost when the experimental drug was not included in Rezimen.
The study was funded by Ellie Lily, which in 2023 acquired Bimagrumb by purchasing Biotech company Versanis Bio for about $ 2 billion. Lily is now testing Bimagramab with her own obesity drug Zepbound (Tirzepatide), a contestant of Vagovi.
One of the most common side effects of weight loss drugs involves muscle mass, a concern that most patients have seen during their weight management journey.
Experts say that muscle loss during rapid weight loss, which is common with obesity drugs or bariatric surgery, may be a serious concern, especially for older adults. This is why drug manufacturers are looking for ways to help patients lose fat when preserving the muscles.
Other companies like Regeneron and Veru are also testing similar drug combinations, but doctors have warned that new combinations may come up with additional side effects. The report stated that in a Regenron test, two patients died, although the company said that there was no direct connection of drugs.
New results provide hope for a safe and more effective way to manage obesity, a one that deal with fat while keeping the body strong.